<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27474345</identifier>
<setSpec>1578-8865</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ginel Mendoza, L</dc:author>
<dc:author>Polo García, J</dc:author>
<dc:author>Quintano Jiménez, J A</dc:author>
<dc:author>Entrenas Costa, L M</dc:author>
<dc:description xml:lang="en">The fixed-dose combination fluticasone propionate/formoterol (FPF) is a novel combination of a widely known and used inhaled glucocorticoid (IGC) and a long-acting β2-adrenergic agonist (LABA), available for the first time in a single device. This fixed-dose combination of FPF has a demonstrated efficacy and safety profile in clinical trials compared with its individual components and other fixed-dose combinations of IGC/LABA and is indicated for the treatment of persistent asthma in adults and adolescents. FPF is available in a wide range of doses that can adequately cover the therapeutic steps recommended by treatment guidelines, constituting a fixed-dose combination of GCI/LABA that is effective, rapid, well tolerated and with a reasonable acquisition cost. Various assessment agencies of the Spanish Autonomous Communities consider this combination to be an appropriate alternative therapy for asthma in the primary care setting.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Formoterol fumarato</dc:subject>
<dc:subject>Broncodilatador</dc:subject>
<dc:subject>Bronchodilator</dc:subject>
<dc:subject>Fluticasona propionato</dc:subject>
<dc:subject>Inhaled corticosteroid</dc:subject>
<dc:subject>Formoterol fumarate</dc:subject>
<dc:subject>Agonista β2-adrenérgico de acción larga</dc:subject>
<dc:subject>Asma</dc:subject>
<dc:subject>Long-acting β2-agonist</dc:subject>
<dc:subject>Glucocorticoides inhalados</dc:subject>
<dc:subject>Asthma</dc:subject>
<dc:subject>Fluticasone propionate</dc:subject>
<dc:date>2016 Feb </dc:date>
<dc:title xml:lang="es">Combinación a dosis fija de fluticasona propionato/formoterol fumarato para el tratamiento del asma: una revisión de la farmacología, eficacia y tolerabilidad.</dc:title>
<dc:title xml:lang="en">[Fixed-dose combination fluticasone propionate/formoterol for the treatment of asthma: a review of its pharmacology, efficacy and tolerability].</dc:title>
<dc:publisher>Semergen</dc:publisher>
</metadata>
</record>
</pubmed-document>
